CME Information

Activity Title Performance Improvement Tool
Topic Idiopathic thrombocytopenic purpura (ITP)
Target Audience Hematologists, hepatologists, oncologists, and other health care professionals with clinical information on diagnosis and management of patients with idiopathic thrombocytopenic purpura (ITP)
Accreditation Type CME
Release Date March 2010
Expiration Date March 31, 2011
Estimated Time to Complete Activity 60 minutes


LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Describe how understanding of the underlying pathophysiology of idiopathic thrombocytopenic purpura (ITP) has evolved in recent years and the implications for therapeutic strategies
  • Assess the benefits and risks of current and emerging pharmacotherapies for ITP including the latest clinical evidence on efficacy and safety of agents that stimulate platelet production
  • Describe the latest clinical evidence on the use of therapies stimulating platelet production in other patient populations prone to thrombocytopenia, including chronic liver disease and cancer patients
  • Discuss recent findings on patient-assessed quality of life measures in ITP and how these issues may affect risk/benefit analyses and therapeutic management decisions in these patients

FACULTY

Robert S. Brown Jr, MD, MPH
Frank Cardile Professor of Medicine and Pediatrics (Surgery)
Columbia University College of Physicians and Surgeons
Chief, Division of Abdominal Organ Transplantation
Director, Center for Liver Disease and Transplantation
New York-Presbyterian Hospital/Columbia University Medical Center
New York, New York

James B. Bussel, MD
Professor of Pediatrics
Professor of Pediatrics in Obstetrics and Gynecology and in Medicine
Weill Medical College of Cornell University
New York, New York

Marc S. Zumberg, MD
Associate Professor
Division of Hematology and Oncology
Department of Medicine
University of Florida
Gainesville, Florida

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME information.
  3. Complete the CME activity
  4. Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Your CME certificate will be emailed to you within 4 weeks.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS

SPONSOR

This activity is sponsored by The France Foundation.

TARGET AUDIENCE

This activity has been planned in accordance with the need to provide hematologists, hepatologists, oncologists, and other health care professionals with clinical information on diagnosis and management of patients with idiopathic thrombocytopenic purpura (ITP).

STATEMENT OF NEED

There are currently limited therapeutic options for the management of ITP and often these may be inappropriate for some patients with ITP. However, there are new therapies for ITP on the horizon, and it is important that clinicians are kept informed on the latest clinical trial results. This education will help hematologists, oncologists, and other health care professionals managing patients with ITP and related thrombocytopenic complications in the areas of diagnosis and management of ITP in a wide variety of clinical situations.

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, The France Foundation will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

DISCLOSURE

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty have indicated they have relationships with industry to disclose relative to the content of this CME activity:

  • Robert S. Brown Jr, MD, MPH, has received grants/research support from Bristol-Myers Squibb, Gilead, and Schering-Plough, and he has received honoraria from Gilead, Roche, and Schering-Plough.
  • James B. Bussel, MD, has received grants/research support from Amgen, Biogen-IDEC, Cangene, Genentech, Genzyme, GlaxoSmithKline, Immunomedics, Ligand, MGI Pharma/Eisai, and Sysmex. He has served as a consultant for Amgen, Baxter, GlaxoSmithKline, and Ligand. He is stock shareholder of Amgen and GlaxoSmithKline, and has received honoraria from Amgen, Baxter, and GlaxoSmithKline.
  • Marc S. Zumberg, MD, has served as a consultant and received honoraria from Amgen and GlaxoSmithKline.

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from GlaxoSmithKline.

DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and GlaxoSmithKline assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2010 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

 

To begin: